Document is current
Any future updates will be listed below
-
Authors
Hong, Sung-Jin
Lee, Yong-Joon
Kang, Woong Chol
Hong, Bum-Kee
Lee, Jong-Young
Lee, Jin-Bae
Yang, Tae-Hyun
Yoon, Junghan
Lee, Seung-Jun
Ahn, Chul-Min
Kim, Jung-Sun
Kim, Byeong-Keuk
Ko, Young-Guk
Choi, Donghoon
Jang, Yangsoo
Hong, Myeong-Ki
,
-
Funding
Funding for this research was provided by:
Sam Jin Pharmaceutical
Chong Kun Dang Pharmaceutical
- License Information
-
More Information
Article History
Received: 24 May 2024
Accepted: 1 August 2024
First Online: 7 August 2024
<!--Emphasis Type='Bold' removed-->Declarations
:
: The protocol for the LODESTAR trial was approved by the Institutional Review Board of each participating center (Yonsei University Health System, Institutional Review Board, 4-2015-0713) and adhered to the ethical principles of the Declaration of Helsinki. All participants provided written informed consent before enrolling in the trial.
: Not applicable.
: M-KH has received speaker’s fees from Medtronic, Edward Lifesciences, and Viatris Korea and institutional research grants from Sam Jin Pharmaceutical and Chong Kun Dang Pharmaceutical. All other authors declare no competing interests.
